NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 798 taking part
- Started
- 30 Jan 2017
- Primary completion
- 1 May 2026
- Arms
- Arm II (nivolumab)
- Results
- None posted
- 15 Jul 2016: Trial registered
- 30 Jan 2017: Trial started